Mangoceuticals, Inc. develops, markets and sells health and wellness products through a secure telemedicine platform under the MangoRx and PeachesRx brands. Company news commonly covers telehealth programs for erectile dysfunction, hair growth, hormone replacement therapy and weight management, including prescription access and fulfillment through pharmacy partners when medically appropriate.
Recurring updates also include product and intellectual-property developments such as MGX-0024, an antiviral animal feed and drinking water additive technology, as well as capital actions, platform operations and legal matters involving technology vendors. The company’s releases often connect its wellness brands, digital consultation model and eCommerce infrastructure to new treatment categories and operating initiatives.
Mangoceuticals (NASDAQ: MGRX) reported early traction for a newly launched all-inclusive injectable Testosterone Replacement Therapy (TRT) program priced at $99/month. MangoRx cites 336% month-over-month sales growth since mid-December and a 54% reduction in customer acquisition cost.
The offer includes doctor visits, labs, and prescribed medication. Management expects TRT to be the primary near-term growth driver while expanding telehealth men’s health services and maintaining regulatory compliance.
Mangoceuticals (NASDAQ: MGRX) closed a registered direct offering and concurrent private placement on December 19, 2025, raising approximately $2.5 million in gross proceeds.
The company sold 1,930,502 Common Units (or Pre-Funded Units) at an offering price of $1.295 per Common Unit (or $1.29499 per Pre-Funded Unit) and issued accompanying PIPE Common Warrants exercisable at $1.4245. Pre-funded warrants are immediately exercisable.
Proceeds are expected to be used for general corporate purposes and working capital. Aegis Capital acted as placement agent; the offering was made under an effective Form S-3 shelf declared effective June 24, 2025.
Mangoceuticals (NASDAQ: MGRX) announced an up to $100 million Solana-focused digital asset treasury (DAT) strategy on Dec 19, 2025 in partnership with Cube Group and a new subsidiary, Mango DAT, LLC.
The MULTI-DAT framework targets staking and DeFi yield with staked 7-8% APY and active management targeting 8-20% APY, and names Cube Group founders (Solana core developers) as asset manager. The company may use its shelf registration and ATM or other offerings to fund accumulation; no guarantee of full funding was stated.
Mangoceuticals (NASDAQ: MGRX) entered definitive agreements for a registered direct offering and a concurrent private placement expected to raise approximately $2.5 million. The transactions consist of the sale of 1,930,502 Common Units (or Pre-Funded Units), each including one share or one pre-funded warrant plus one PIPE Common Warrant to buy one share at an exercise price of $1.4245. The offering price per Common Unit is $1.295 (Pre-Funded Unit $1.29499). The offerings are priced at the market under Nasdaq rules and are expected to close on or about December 19, 2025, subject to customary conditions. Proceeds are intended for general corporate purposes and working capital. The registered offering relies on an effective Form S-3 declared effective June 24, 2025, and the company has agreed to registration rights for resale of issued securities.
Mangoceuticals (NASDAQ: MGRX) clarified that its newly launched MangoRx Direct and PeachesRx Direct weight-management programs are live as of November 14, 2025, offering telehealth consultations, personalized care plans, and ongoing support for $99 per month (medication cost separate).
Through a vetted third-party provider, the programs can facilitate valid prescriptions for FDA-approved branded GLP-1 medications, including Zepbound and Wegovy, and patients may fill prescriptions at any licensed pharmacy or manufacturer self-pay channels, subject to manufacturer supply availability. Mangoceuticals confirmed it has no direct contract with Eli Lilly or Novo Nordisk.
Mangoceuticals (NASDAQ: MGRX) launched MangoRx Direct and PeachesRx Direct on Nov 13, 2025 to provide telehealth access, clinical monitoring, and fulfillment for branded GLP-1 obesity drugs Zepbound (tirzepatide) via LillyDirect and Wegovy (semaglutide) via NovoCare. The company offers a medication-management membership at $99/month and states GLP-1 drugs are available at fixed cash-pay pricing starting $499/month with home delivery or local pharmacy pickup.
The release also notes a Novo Nordisk spokesperson saying Novo Nordisk has no agreement with Mangoceuticals, and references White House pricing initiatives targeting $245/month government prices and other program pricing changes in 2026.
Mangoceuticals (NASDAQ: MGRX) has announced the acquisition of Smokeless Technology Corp.'s intellectual property and related assets, marking its strategic entry into the oral pouch delivery market. The acquisition includes product formulations, know-how, distribution, and supplier relationships from the Canadian-based pouch innovation company.
The company plans to integrate Smokeless Tech's stimulant formulations with pharmaceutical ingredients under the MangoRx and PeachesRx brands. According to Skyquest, the U.S. nicotine pouch market reached $3.13 billion in 2024, with projections for the global oral pouch market to exceed $37.34 billion by 2032.
Additionally, MGRX has appointed Tim Corkum, former President of JUUL Labs Canada and Philip Morris International executive, to lead their pouch division. The company aims to leverage its existing distribution network, compounding pharmacy relationships, and planned Diabetinol launch to position itself as a nutraceutical platform with multi-format delivery potential.
Mangoceuticals Inc. (NASDAQ:MGRX) is expanding its presence in the health and wellness sector through innovative product offerings. The company's flagship product, Mango, offers ED treatment in two versions: Sildenafil Mango and Tadalafil Mango, featuring fast-acting dissolvable tablets with unique formulations.
The company's portfolio includes:
- Prime by MangoRx: A telehealth-enabled testosterone replacement therapy using Kyzatrex™, an FDA-approved oral testosterone capsule
- Grow by MangoRx: A comprehensive hair loss treatment combining Minoxidil, Finasteride, Biotin, and Vitamin D3
- Slim by MangoRx: An oral dissolving Semaglutide tablet for weight loss
- Diabetinol®: A patented plant-based nutraceutical for metabolic health
The company has also launched PeachesRx, a women's wellness brand, expanding their reach beyond men's health to create a comprehensive wellness ecosystem.
Mangoceuticals (NASDAQ: MGRX) has secured exclusive licensing and distribution rights for Diabetinol® in the United States and Canada, entering the $33.66 billion diabetes and metabolic health market. Diabetinol® is a patented plant-based nutraceutical derived from citrus peel, clinically proven to improve insulin sensitivity and metabolic function.
The product will be distributed in multiple formats including capsules, beverages, pouches, cookies, and gummies through direct-to-consumer channels, online retailers, brick-and-mortar stores, and affiliate marketing. The expansion targets the growing diabetes crisis, with over 30 million Americans suffering from type 2 diabetes and 97.6 million adults having prediabetes.
The company positions Diabetinol® as a more affordable alternative for individuals who cannot access or tolerate GLP-1 medications, addressing a significant market need as U.S. diabetes-related healthcare costs exceed $400 billion annually.